Recent developments in drug-induced movement disorders: a mixed picture.

Abstract

A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people. Prevention of the development of drug-induced movement disorders is an important consideration when prescribing medications that can induce movement disorders. Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders. Future research should focus on development of safer antipsychotics and specific therapies for the different tardive syndromes and the treatment of drug-induced parkinsonism.

• Authors: Stewart A Factor, Pierre R Burkhard, Stanley Caroff, Joseph H Friedman, Connie Marras, Michele Tinazzi, Cynthia L Comella
• Journal: The Lancet. Neurology (Lancet Neurol) Vol. 18 Issue 9 Pg. 880-890 (09 2019) ISSN: 1474-4465 [Electronic] England
• PMID: 31279747 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 Elsevier Ltd. All rights reserved.

Chemical References

• Antipsychotic Agents

Topics

• Antipsychotic Agents (adverse effects)
• Disease Management
• Dyskinesia, Drug-Induced (diagnosis, prevention & control, therapy)
• Humans